Sign up to save your podcasts
Or
Share Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2525 ratings
Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
JAMA Editors' Summary
137 Listeners
AFP: American Family Physician Podcast
699 Listeners
JAMA Clinical Reviews
497 Listeners
JACC This Week
168 Listeners
Diabetes Core Update
103 Listeners
This Week in Cardiology
881 Listeners
The Bob Harrington Show
14 Listeners
One-on-One with Eric Topol
16 Listeners
Mayo Clinic Talks
292 Listeners
Frankly Speaking About Family Medicine
262 Listeners
The Curbsiders Internal Medicine Podcast
3,350 Listeners
Core IM | Internal Medicine Podcast
1,146 Listeners
Annals On Call Podcast
193 Listeners
JAMA Medical News
93 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
Freely Filtered, a NephJC Podcast
172 Listeners
Medicine and the Machine
61 Listeners
Keeping Current
8 Listeners
Cardionerds: A Cardiology Podcast
425 Listeners